TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Correlation of symptomatology with inflammatory profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Binocular Best-corrected Distance Visual Acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sucralose concentrations in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acesulfame-potassium concentrations in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sucralose concentrations in maternal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acesulfame-potassium concentrations in maternal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sucralose concentrations in infant plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acesulfame-potassium concentrations in infant plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in upright vs non-upright position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLACC Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trace elements concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection rate of gallium Ga 68 gozetotide (68Ga-PSMA-11) PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flow mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: spontaneous neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fluctuations of venous blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal arterial hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positivity of passive leg raise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive passive leg raise test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Any stroke (disabling and non-disabling)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Exam Completion Rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Detection of middle ear fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Categorization of middle ear fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-1 beta levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tract damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective effects I
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective effects II
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective remission rate (ORR) determined by Independent Review Committee (IRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of therapy discontinuation due to any event
Endpoint domain: Adverse events/effects
Primary endpoint: decline in renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: plasma level of interleukin 38
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Blood Urea Nitrogen (BUN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of chronic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of feasibility assessment of the investigational device (application) questionnaire for subjects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score of feasibility assessment of the investigational device (website) questionnaire for investigators
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Days of Headache per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak diastolic velocity (PDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Bleeding Score (BS - Mombelli et al.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, type, and severity of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Morphology of device capsule tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histology of device capsule tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thalf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Domain-specific Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of nerve impulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vertical jump speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in neutrophil to lymphocyte ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in platelet to lymphocyte ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oral microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of vaccine regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of vaccine regimens
Endpoint domain: Adverse events/effects
Primary endpoint: Self-referencing bias measured by response accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-referencing bias measured by response time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients in steroid-free clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners-3 Parent Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IL-6 Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTB cfDNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Time to first detection of AF lasting > 5 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 24-h Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Concentration-time (AUC) of Brensocatib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured by Visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from HbA1c level at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from basal capillary blood glucose at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Support for stopping screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best monocular uncorrected distance visual acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best monocular corrected distance visual acuity (CDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Eptinezumab Plasma Concentration-Time Curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of skeletal muscle mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of appendicular skeletal muscle mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of tissue sodium content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants that changed lymphedema severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ankle swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Symptoms Score on Allergic Rhinitis at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference from Baseline in Quality of Life Questionnaire on several domains at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in Total Nasal Resistance while normal breathing at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physical Activity and Social Support Scale (PASSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Static pressure distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posturographic center of gravity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posturographic average sway velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency department visits due to injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Child development (K-Bayley-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal self-rated health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mechanical Ventilation days until successful extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients who decide to enroll in an immunotherapy clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients who remain in immunotherapy clinical trial to trial completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ANI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Carpal Tunnel Questionnaire (BCTQ) scale (SSS, FSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6-item CTS symptoms scale (CTS-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reading speed following training sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: face discrimination threshold following training sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: video comprehension (shared word score) following training sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed for epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whether or not the frontal neo-ostium was restenosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of participants choosing ANDS or no tobacco
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absence of atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Colour sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response of anti-cancer therapy at first evaluation in patients with lung cancer/pulmonary nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in level of Aspartate transaminase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of Alanine transaminase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin Score of 0-3
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment allocation rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Home-based cardiac rehabilitation exercise adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Enrolled Per Month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Enrollees Satisfied With Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Weekly Pain Severity and Frequency Assessments Completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability and reproducibility coefficients of LiverScope® PDFF measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of LiverScope® PDFF measurements with MRI PDFF measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific batokine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Funduscopic examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of nal-IRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield in detecting a bleeding site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetaminophen Serum Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CHOP INTEND score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in HINE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of the algorithm for COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [11C]acetate uptake in renal angiomyolipoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: [11C]acetate uptake in pulmonary LAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: White matter morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gray matter morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive Parenting Practices
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Parent Satisfaction with App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Main neurocognitive outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of event of intubation or pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve for imatinib from time zero to last measurable concentration (AUC(0-last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve for imatinib from time zero to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of imatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and temporal profile of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of those in each dosing cohort who discontinued the assigned regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Assessment by fractional flow reserve (FFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment by contrast fractional flow reserve (cFFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: psychosocial dimension of patients' quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: International Prostate Symptom Score (IPSS) Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device Related Serious Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Total All-cause Medical Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of decision about screening participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall survival (OS) less than 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Numeric Rating Scale of post-accident syndromes
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Preference for opioids with THC/CBD vs opioids alone
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Left Ventricular Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-Trivial Pericardial Effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Ventricular Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of anaesthesia withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NHE1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Malaria incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in discharge time of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Instrumented Timed Up and Go test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute safety as assessed by the rate of acute adjudicated device-, treatment-, and procedure-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Quality of Life as evaluated by the Kansas City Quality of Life Questionnaire (KCCQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Long term patient outcomes as evaluated by the time (days) to rehospitalization for acute decompensated heart failure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall Correct Initial TASS Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Correct Final Use Outcome With Mitigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Verified LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gene profile in tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior knee pain scale (Kujala)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in neuropathy severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sunnybrook Grading Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Synkinesis Assessment Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Continuation of pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Rate of clinically significant recovery of exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI ≤ 40 kg/m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall attendance of program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall treatment adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in life satisfaction level
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Healthism Attitude level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment-Induced Neuropathy Assessment Scale (TNAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain intensity: VAS - 0-100 mm visual scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley-III Cognitive Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Public Health Surveillance of Fruit and Vegetable Intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status